ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 15 for:    "RWJMS" OR "Robert Wood Johnson Medical School" OR "Cancer Institute of New Jersey" OR "CINJ" | Recruiting, Not yet recruiting, Available Studies | "Lung Neoplasms"

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03229278
Recruitment Status : Recruiting
First Posted : July 25, 2017
Last Update Posted : May 25, 2018
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Ann (Annie) W. Silk, M.D., M.S., Rutgers Cancer Institute of New Jersey

Brief Summary:
This phase I trial studies the best dose and side effects of trigriluzole in combination with nivolumab and pembrolizumab in treating patients with solid malignancies or lymphoma that has spread to other places in the body or cannot be removed by surgery. Trigriluzole may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab and pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving trigriluzole in combination with nivolumab and pembrolizumab may work better at treating patients with solid malignancies or lymphoma.

Condition or disease Intervention/treatment Phase
Lymphoma Metastatic Malignant Solid Neoplasm Metastatic Melanoma Metastatic Renal Cell Cancer Recurrent Bladder Carcinoma Recurrent Classical Hodgkin Lymphoma Recurrent Head and Neck Squamous Cell Carcinoma Recurrent Lymphoma Recurrent Malignant Solid Neoplasm Recurrent Renal Cell Carcinoma Stage III Bladder Cancer Stage III Lymphoma Stage III Non-Small Cell Lung Cancer AJCC v7 Stage III Renal Cell Cancer Stage III Skin Melanoma Stage IIIA Non-Small Cell Lung Cancer AJCC v7 Stage IIIA Skin Melanoma Stage IIIB Non-Small Cell Lung Cancer AJCC v7 Stage IIIB Skin Melanoma Stage IIIC Skin Melanoma Stage IV Bladder Cancer Stage IV Lymphoma Stage IV Non-Small Cell Lung Cancer AJCC v7 Stage IV Renal Cell Cancer Stage IV Skin Melanoma Stage IVA Bladder Cancer Stage IVB Bladder Cancer Unresectable Head and Neck Squamous Cell Carcinoma Unresectable Solid Neoplasm Drug: Enzyme Inhibitor Therapy Other: Laboratory Biomarker Analysis Biological: Nivolumab Biological: Pembrolizumab Phase 2

Detailed Description:

PRIMARY OBJECTIVES:

I. The primary objective of this study is to determine the safety of trigriluzole in combination with PD-1 inhibiting antibodies, and to define a maximum tolerated dose (MTD) of trigriluzole in combination therapy.

SECONDARY OBJECTIVES:

I. To characterize the efficacy of the combination therapy. II. To identify markers of response to trigriluzole in the tumor microenvironment.

OUTLINE: This is a dose-escalation study of trigriluzole.

Patients receive trigriluzole orally (PO) every other day (QOD), twice daily (BID), every morning (QAM) or every bedtime (QHS) on days -14 to -1. Patients then receive nivolumab intravenously (IV) over 60 minutes every 2 weeks beginning week 1 and trigriluzole PO QOD, BID, QAM or QHS. Once the MTD of trigriluzole with nivolumab is identified, patients receive pembrolizumab IV over 30 minutes every 3 weeks beginning week 1 and trigriluzole PO. Treatment repeats for up to 1 year in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 12 weeks for up to 3 years.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 27 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study to Evaluate the Safety of Trigriluzole (FC-4157/BHV-4157) in Combination With PD-1 Blocking Antibodies
Actual Study Start Date : August 17, 2017
Estimated Primary Completion Date : July 30, 2019
Estimated Study Completion Date : July 30, 2019


Arm Intervention/treatment
Experimental: Treatment (trigriluzole, nivolumab, pembrolizumab)
Patients receive trigriluzole PO QOD, BID, QAM or QHS on days -14 to -1. Patients then receive nivolumab IV over 60 minutes every 2 weeks beginning week 1 and trigriluzole PO QOD, BID, QAM or QHS. Once the MTD of trigriluzole with nivolumab is identified, patients receive pembrolizumab IV over 30 minutes every 3 weeks beginning week 1 and trigriluzole PO. Treatment repeats for up to 1 year in the absence of disease progression or unacceptable toxicity.
Drug: Enzyme Inhibitor Therapy
Given trigriluzole PO

Other: Laboratory Biomarker Analysis
Correlative studies

Biological: Nivolumab
Given IV
Other Names:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo

Biological: Pembrolizumab
Given IV
Other Names:
  • Keytruda
  • Lambrolizumab
  • MK-3475
  • SCH 900475




Primary Outcome Measures :
  1. Maximum tolerated dose (MTD))/recommended phase 2 dose of trigriluzole [ Time Frame: Up to 3 years ]
    The MTD of trigriluzole in combination with nivolumab will be identified. The MTD will then be tested in combination with pembrolizumab using the same escalate/de-escalate/stay rules. Data on the adverse event type, severity and frequency will be recorded.


Secondary Outcome Measures :
  1. Adverse event (AE) type, severity and frequency [ Time Frame: Up to 3 years ]
    The frequency of AEs and serious AEs will be recorded.

  2. Objective response rate assessed according to Response Evaluation Criteria in Solid Tumors version 1.1 [ Time Frame: Up to 3 years ]
    Continuous variables will be presented by summary statistics (such as mean, median, standard error and 90% confidence intervals [CI]) and the categorical variables by frequency distributions (i.e., frequency counts, percentages and 90% CI).

  3. Overall survival [ Time Frame: Up to 3 years ]
    Continuous variables will be presented by summary statistics (such as mean, median, standard error and 90% CI) and the categorical variables by frequency distributions (i.e., frequency counts, percentages and 90% CI).

  4. Landmark survival rates [ Time Frame: 1 year ]
    Continuous variables will be presented by summary statistics (such as mean, median, standard error and 90% CI) and the categorical variables by frequency distributions (i.e., frequency counts, percentages and 90% CI).

  5. Landmark survival rates [ Time Frame: 2 years ]
    Continuous variables will be presented by summary statistics (such as mean, median, standard error and 90% CI) and the categorical variables by frequency distributions (i.e., frequency counts, percentages and 90% CI).

  6. Duration of response for responding patients [ Time Frame: Up to 3 years ]
    Continuous variables will be presented by summary statistics (such as mean, median, standard error and 90% CI) and the categorical variables by frequency distributions (i.e., frequency counts, percentages and 90% CI).

  7. Progression-free survival [ Time Frame: Up to 3 years ]
    Continuous variables will be presented by summary statistics (such as mean, median, standard error and 90% CI) and the categorical variables by frequency distributions (i.e., frequency counts, percentages and 90% CI).

  8. Time to treatment failure [ Time Frame: Up to 3 years ]
    Continuous variables will be presented by summary statistics (such as mean, median, standard error and 90% CI) and the categorical variables by frequency distributions (i.e., frequency counts, percentages and 90% CI).

  9. Time to next therapy or death [ Time Frame: Up to 3 years ]
    Continuous variables will be presented by summary statistics (such as mean, median, standard error and 90% CI) and the categorical variables by frequency distributions (i.e., frequency counts, percentages and 90% CI).

  10. Freedom from new metastases [ Time Frame: Up to 3 years ]
    Continuous variables will be presented by summary statistics (such as mean, median, standard error and 90% CI) and the categorical variables by frequency distributions (i.e., frequency counts, percentages and 90% CI).


Other Outcome Measures:
  1. Change in angiogenesis markers [ Time Frame: Baseline up to 3 years ]
    Treatment effect for each patient will be measured as paired differences between pre- and post- measurements of these parameters at various times. Transformation of the data will be performed if appropriate, e.g. log transformation, and hence treatment effect will be expressed on a log scale. This analysis of the data obtained in these correlative studies will be descriptive in nature.

  2. Change in exosomal formation [ Time Frame: Baseline up to 3 years ]
    Treatment effect for each patient will be measured as paired differences between pre- and post- measurements of these parameters at various times. Transformation of the data will be performed if appropriate, e.g. log transformation, and hence treatment effect will be expressed on a log scale. This analysis of the data obtained in these correlative studies will be descriptive in nature.

  3. Change in immune cell phenotypes and gene expression [ Time Frame: Baseline up to 3 years ]
    Treatment effect for each patient will be measured as paired differences between pre- and post- measurements of these parameters at various times. Transformation of the data will be performed if appropriate, e.g. log transformation, and hence treatment effect will be expressed on a log scale. This analysis of the data obtained in these correlative studies will be descriptive in nature.

  4. Change in metabolic effector molecules [ Time Frame: Baseline up to 3 years ]
    Treatment effect for each patient will be measured as paired differences between pre- and post- measurements of these parameters at various times. Transformation of the data will be performed if appropriate, e.g. log transformation, and hence treatment effect will be expressed on a log scale. This analysis of the data obtained in these correlative studies will be descriptive in nature.

  5. Change in tumor infiltrating lymphocyte (TIL)s and PD-L1 expression [ Time Frame: Baseline up to 3 years ]
    Treatment effect for each patient will be measured as paired differences between pre- and post- measurements of these parameters at various times. Transformation of the data will be performed if appropriate, e.g. log transformation, and hence treatment effect will be expressed on a log scale. This analysis of the data obtained in these correlative studies will be descriptive in nature.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have histologically confirmed solid malignancy or lymphoma that is metastatic or unresectable
  • There is reasonable expectation of response to pembrolizumab or nivolumab, and one of the drugs is available from the commercial supply; this includes (but is not limited to) the following tumor types: melanoma, non-small cell lung cancer, renal cell carcinoma, squamous cell carcinoma of the head and neck, bladder cancer, and classic Hodgkin lymphoma
  • The patient must have failed at least one line of standard treatment, with the following exceptions in which a PD-1 antibody is Food and Drug Administration (FDA) approved in the first-line setting:

    • Melanoma patients
    • Non-small cell lung cancer patients without EGFR or ALK genomic tumor aberrations whose tumors have high PD-L1 expression (tumor proportion score [TPS] >= 50%) as determined by an FDA-approved test
  • Patients must give informed consent
  • Prior chemotherapy, immunotherapy, radiotherapy or major surgery (including radiation therapy or surgery for treatment of brain metastases) must be completed at least 3 weeks before study entry; prior PD-1 or PD-L1 therapy is acceptable
  • Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status =< 2
  • Hemoglobin > 8.0 mg/dL (without transfusion in the preceding 7 days)
  • Platelets >= 70,000 /uL
  • Total bilirubin within normal institutional limits (patients with Gilbert's syndrome must have a total bilirubin < 3.0 mg/dL)
  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) =< 2 X institutional upper limit of normal (ULN)
  • Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2 X institutional ULN
  • Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 10 mm by computed tomography (CT) scan, positron emission tomography (PET)/CT scan, magnetic resonance imaging (MRI) or caliper/ruler measurement by clinical exam; lymph nodes: to be considered pathologically enlarged and measurable, a lymph node must be >= 15 mm in short axis when assessed by CT scan; lesions that have been radiated in the advanced setting cannot be included as sites of measurable disease unless clear tumor progression has been documented in these lesions since the end of radiation therapy
  • Ability to swallow pills

Exclusion Criteria:

  • Systemic immunosuppressive medications such as steroids; the following steroid formulations are permitted: intranasal, intra-articular, and inhaled steroids
  • History of immune-related adverse event from prior immunotherapy treatment that has not improved to grade 0-1; subjects with grade 2 hypothyroidism and grade 2 adrenal insufficiency requiring continued medical treatment may enroll provided that they are asymptomatic and stable on their dose of hormone replacement
  • Serious concomitant systemic disorders (including active infections) that would compromise the safety of the patient or compromise the patient?s ability to complete the study, at the discretion of the investigator, including active autoimmune disease requiring treatment within the past 30 days
  • Any condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other systemic immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses < 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption)' physiologic replacement doses of systemic corticosteroids are permitted, even if < 10 mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted
  • Second primary malignancy, except those second primary malignancies that are not considered to be competing causes of death in the opinion of the treating investigator; examples include: in situ carcinoma of the cervix, adequately treated non-melanoma carcinoma of the skin, or other malignancy treated at least 5 years previously with no evidence of recurrence
  • Patients with active, untreated central nervous system (CNS) metastases will be excluded from this clinical trial; patients who have brain metastases that been treated with radiation therapy or surgery will be required to have a washout period of at least 3 weeks prior to study entry, must be neurologically asymptomatic, and must not require systemic steroids
  • Women of child-bearing potential and men must agree to use adequate contraception prior to the start of treatment, for the duration of treatment, and for 5 months after last dose of study treatment
  • Patients with immune deficiency have impaired immune responses, therefore, known human immunodeficiency virus (HIV)-positive patients are excluded from the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03229278


Locations
United States, New Jersey
Rutgers Cancer Institute of New Jersey Recruiting
New Brunswick, New Jersey, United States, 08903
Contact: Ann (Annie) W. Silk    732-235-8675    as2300@cinj.rutgers.edu   
Principal Investigator: Ann (Annie) W. Silk         
Sponsors and Collaborators
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)
Investigators
Principal Investigator: Ann (Annie) Silk Rutgers Cancer Institute of New Jersey

Responsible Party: Ann (Annie) W. Silk, M.D., M.S., Assistant Professor, Medical Oncology, Rutgers Cancer Institute of New Jersey
ClinicalTrials.gov Identifier: NCT03229278     History of Changes
Other Study ID Numbers: 051707
NCI-2017-01155 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
Pro20170000453
051707 ( Other Identifier: Rutgers Cancer Institute of New Jersey )
P30CA072720 ( U.S. NIH Grant/Contract )
First Posted: July 25, 2017    Key Record Dates
Last Update Posted: May 25, 2018
Last Verified: May 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Lung Neoplasms
Lymphoma
Carcinoma
Neoplasms
Carcinoma, Non-Small-Cell Lung
Melanoma
Carcinoma, Squamous Cell
Hodgkin Disease
Urinary Bladder Neoplasms
Carcinoma, Renal Cell
Head and Neck Neoplasms
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Neoplasms, Glandular and Epithelial
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Nevi and Melanomas
Neoplasms, Squamous Cell